Edition:
United Kingdom

Cidara Therapeutics Inc (CDTX.OQ)

CDTX.OQ on NASDAQ Stock Exchange Global Market

7.10USD
15 Dec 2017
Change (% chg)

$0.00 (+0.00%)
Prev Close
$7.10
Open
$7.10
Day's High
$7.30
Day's Low
$6.90
Volume
28,343
Avg. Vol
20,651
52-wk High
$11.73
52-wk Low
$5.60

Select another date:

Tue, Nov 28 2017

BRIEF-Cidara Therapeutics Completes Enrollment in Phase 2 Strive Trial for Antifungal Rezafungin

* CIDARA THERAPEUTICS COMPLETES ENROLLMENT IN PHASE 2 STRIVE TRIAL EVALUATING NOVEL ANTIFUNGAL REZAFUNGIN (CD101 IV) IN INVASIVE FUNGAL INFECTIONS Source text for Eikon: Further company coverage:

BRIEF-Cidara Therapeutics announces pricing of $20 mln private placement

* Cidara Therapeutics announces pricing of $20 million private placement of common stock

BRIEF-Cidara Q2 net loss per share $0.99​

* Cidara provides corporate update and reports second quarter 2017 financial results

BRIEF-Cidara Therapeutics updates on results from studies investigating antifungal CD101

* Cidara therapeutics inc - ‍announces publication of results from in vivo study investigating novel antifungal CD101 in intra-abdominal candidiasis (IAC)​

BRIEF-Broadfin Capital reports 5.28 percent passive stake in Cidara Therapeutics as of July 7

* Broadfin Capital LLC reports a 5.28 percent passive stake in Cidara Therapeutics Inc as of July 7, 2017 - SEC filing Source text for Eikon: Further company coverage:

BRIEF-Prosight Management LP reports 5.2 pct passive stake in Cidara Therapeutics - SEC filing

* Prosight Management LP reports a 5.2 percent passive stake in Cidara Therapeutics Inc as of June 7, 2017 - SEC filing Source text - (http://bit.ly/2rEN8RH) Further company coverage:

Select another date: